Together, these findings highlight a potential synergistic relationship between elevated CEACAM1 expression and disrupted TGF-β signaling components, such as SMAD3 and SMAD4, in driving poor clinical outcomes in CRC. The gene discussed is SMAD4; the disease is colorectal carcinoma.